These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22127198)

  • 1. Odd odds.
    Andrade C
    J Clin Psychiatry; 2011 Nov; 72(11):1558-9; author reply 1559. PubMed ID: 22127198
    [No Abstract]   [Full Text] [Related]  

  • 2. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials.
    Carpenter DJ; Fong R; Kraus JE; Davies JT; Moore C; Thase ME
    J Clin Psychiatry; 2011 Nov; 72(11):1503-14. PubMed ID: 21367354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of paroxetine on thyroid hormone levels in severely depressed patients.
    König F; Hauger B; von Hippel C; Wolfersdorf M; Kaschka WP
    Neuropsychobiology; 2000; 42(3):135-8. PubMed ID: 11015031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients.
    Hwang JP; Yang CH; Tsai SJ
    Int J Geriatr Psychiatry; 2004 Feb; 19(2):189-90. PubMed ID: 14758586
    [No Abstract]   [Full Text] [Related]  

  • 5. Antidepressants and children. Buried data can be hazardous to a company's health.
    Marshall E
    Science; 2004 Jun; 304(5677):1576-7. PubMed ID: 15192185
    [No Abstract]   [Full Text] [Related]  

  • 6. Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials.
    Serretti A; Gibiino S; Drago A
    J Affect Disord; 2011 Jul; 132(1-2):14-25. PubMed ID: 20863574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Even more suicide attempts in clinical trials with paroxetine randomised against placebo.
    Aursnes I; Tvete IF; Gaasemyr J; Natvig B
    BMC Psychiatry; 2006 Nov; 6():55. PubMed ID: 17129393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
    Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of controlled-release paroxetine.
    Golden RN
    Psychopharmacol Bull; 2003; 37 Suppl 1():176-86. PubMed ID: 14566210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should paroxetine be used to treat depression during pregnancy?
    Mintzes B; Jureidini J
    Am J Psychiatry; 2008 Nov; 165(11):1487; author reply 1487-8. PubMed ID: 18981077
    [No Abstract]   [Full Text] [Related]  

  • 11. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual and auditory hallucinations during normal use of paroxetine for treatment of major depressive disorder.
    Monji A; Kato T; Mizoguchi Y; Horikawa H; Seki Y; Kanba S
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E14-5. PubMed ID: 22231326
    [No Abstract]   [Full Text] [Related]  

  • 13. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withdrawal after discontinuation of paroxetine.
    Arya DK
    Aust N Z J Psychiatry; 1996 Oct; 30(5):702. PubMed ID: 8902183
    [No Abstract]   [Full Text] [Related]  

  • 15. An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder.
    Ballesteros J; Callado LF; Gutiérrez M
    J Clin Psychopharmacol; 2007 Apr; 27(2):219-21. PubMed ID: 17414254
    [No Abstract]   [Full Text] [Related]  

  • 16. Exacerbation of extrapyramidal symptoms with paroxetine.
    Arya DK; McKenzie J; Worrall N
    Aust N Z J Psychiatry; 1995 Sep; 29(3):521-2. PubMed ID: 8573063
    [No Abstract]   [Full Text] [Related]  

  • 17. Paroxetine: a review of clinical experience.
    Dunner D; Kumar R
    Pharmacopsychiatry; 1998 May; 31(3):89-101. PubMed ID: 9657236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paroxetine and Study 329: what we already knew and when.
    Sasich LD
    BMJ; 2015 Oct; 351():h5411. PubMed ID: 26468042
    [No Abstract]   [Full Text] [Related]  

  • 19. Withdrawal symptoms associated with paroxetine discontinuation in a nine-year-old boy.
    Diler RS; Tamam L; Avci A
    J Clin Psychopharmacol; 2000 Oct; 20(5):586-7. PubMed ID: 11001250
    [No Abstract]   [Full Text] [Related]  

  • 20. Putting GlaxoSmithKline to the test over paroxetine.
    Doshi P
    BMJ; 2013 Nov; 347():f6754. PubMed ID: 24222673
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.